Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

2.6K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
2.6K
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.7K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.7K
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

2.9K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.9K
Chronic Obstructive Pulmonary Disease01:22

Chronic Obstructive Pulmonary Disease

1.4K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.4K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

314
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
314
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

3.1K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Airway wall thickness and PRISm are associated with cognitive impairment in individuals with cigarette smoking exposure.

Respiratory research·2026
Same author

Reply to Liu et al.: Beyond Frequency: Rethinking Exacerbation Risk in COPD.

American journal of respiratory and critical care medicine·2026
Same author

Beyond spirometry in COPD: expanding the diagnostic paradigm.

ERJ open research·2026
Same author

Performance of multivariable risk prediction algorithms in predicting COPD exacerbations: a population-based study.

Thorax·2026
Same author

Summary of Research: Dupilumab for Chronic Obstructive Pulmonary Disease with Type 2 Inflammation: A Pooled Analysis of Two Phase 3, Randomised, Double-Blind, Placebo-Controlled Trials.

Pulmonary therapy·2026
Same author

Defining disease stability in COPD: Evidence from Phase 3 clinical trials.

American journal of respiratory and critical care medicine·2026

Related Experiment Video

Updated: Sep 13, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.2K

Imaging Endpoints for Biologic Therapy in Chronic Obstructive Pulmonary Disease.

Muhammad F A Chaudhary1, Surya P Bhatt2

  • 1Division of Pulmonary, Allergy, and Critical Care Medicine, UAB Heersink School of Medicine, Birmingham, AL, 35233.

The British Journal of Radiology
|July 31, 2025
PubMed
Summary

Chronic obstructive pulmonary disease (COPD) exacerbations can be reduced by biologics targeting type 2 inflammation. Imaging biomarkers like airway wall thickness show promise for tracking disease modification in clinical trials.

Keywords:
BiologicsChronic Obstructive Pulmonary DiseaseComputed TomographyMagnetic Resonance ImagingTreatment Response

More Related Videos

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice
07:38

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

Published on: April 13, 2018

11.6K
Multi-modal Pulmonary Imaging: Using Complementary Information from CT and Hyperpolarized 129Xe MRI to Evaluate Lung Structure-Function
02:09

Multi-modal Pulmonary Imaging: Using Complementary Information from CT and Hyperpolarized 129Xe MRI to Evaluate Lung Structure-Function

Published on: April 12, 2024

681

Related Experiment Videos

Last Updated: Sep 13, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.2K
A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice
07:38

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

Published on: April 13, 2018

11.6K
Multi-modal Pulmonary Imaging: Using Complementary Information from CT and Hyperpolarized 129Xe MRI to Evaluate Lung Structure-Function
02:09

Multi-modal Pulmonary Imaging: Using Complementary Information from CT and Hyperpolarized 129Xe MRI to Evaluate Lung Structure-Function

Published on: April 12, 2024

681

Area of Science:

  • Pulmonology
  • Immunology
  • Radiology

Background:

  • Chronic obstructive pulmonary disease (COPD) significantly impacts respiratory health, marked by exacerbations and progressive decline.
  • A specific endotype of COPD involves type 2 inflammation, linked to increased exacerbations and treatment response.

Purpose of the Study:

  • To explore the utility of imaging biomarkers for assessing disease modification in COPD patients treated with biologics.
  • To evaluate if imaging measures can serve as effective clinical trial endpoints for COPD therapies.

Main Methods:

  • Review of evidence from clinical trials, primarily in asthma, focusing on biologics targeting type 2 inflammation.
  • Analysis of imaging parameters such as airway wall thickness, mucus plugging, and ventilation defect percentage.

Main Results:

  • Biologics targeting type 2 inflammation show potential in reducing COPD exacerbations and improving lung function.
  • Imaging measures including airway wall thickness and mucus plugging appear modifiable with biologic therapy.

Conclusions:

  • Imaging endpoints offer a promising approach to evaluate disease modification and structural remodeling in COPD clinical trials.
  • These endpoints may significantly reduce the sample size needed for trials investigating biologic therapies in COPD.